TY - JOUR
T1 - The neurometabolic landscape of cognitive decline
T2 - In vivo studies with positron emission tomography in Alzheimer's disease
AU - Pietrini, Pietro
AU - Alexander, Gene E.
AU - Furey, Maura L.
AU - Hampel, Harald
AU - Guazzelli, Mario
N1 - Funding Information:
The authors wish to thank Drs Stanley I. Rapoport, Mark B. Schapiro and Alessio Dani for their dedicated support to the research projects presented in this review; Dr Peter Herscovitch for the excellent organization of the PET facilities at the NIH; the PET Dept. technologists, headed by Paul Baldwin, for their precious assistance with PET scanning. Supported by the NIH Intramural Program. Dr Guazzelli was partially supported by the Italian Minister of University and Scientific and Technological Research and the National Research Council of Italy.
PY - 2000/7/1
Y1 - 2000/7/1
N2 - Alzheimer's disease, the most common form of dementia in the elderly, is characterized by the progressive, global and irreversible deterioration of cognitive abilities. The development of positron emission tomography (PET) methodologies has made it possible to study the in vivo brain metabolic correlates of human cognitive and behavioral functions. Moreover, as PET scan examinations can be repeated, the progression of the neuropathological process and its relation to cognitive dysfunction can be followed over time. In an effort to understand the changes in neural function that precede and accompany onset of dementia and their relation to clinical manifestations, in the last several years, we have conducted clinical, neuropsychological and brain metabolic studies in groups of Alzheimer's disease patients at different stages of dementia severity or with distinct clinical pictures and in populations at risk for developing the disease. Here, we discuss the main findings and implications obtained from these studies. Copyright (C) 2000 Elsevier Science B.V.
AB - Alzheimer's disease, the most common form of dementia in the elderly, is characterized by the progressive, global and irreversible deterioration of cognitive abilities. The development of positron emission tomography (PET) methodologies has made it possible to study the in vivo brain metabolic correlates of human cognitive and behavioral functions. Moreover, as PET scan examinations can be repeated, the progression of the neuropathological process and its relation to cognitive dysfunction can be followed over time. In an effort to understand the changes in neural function that precede and accompany onset of dementia and their relation to clinical manifestations, in the last several years, we have conducted clinical, neuropsychological and brain metabolic studies in groups of Alzheimer's disease patients at different stages of dementia severity or with distinct clinical pictures and in populations at risk for developing the disease. Here, we discuss the main findings and implications obtained from these studies. Copyright (C) 2000 Elsevier Science B.V.
KW - Brain metabolism
KW - Cognition
KW - Dementia
KW - Early diagnosis
KW - Human
KW - Synaptic dysfunction
UR - http://www.scopus.com/inward/record.url?scp=0034237167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034237167&partnerID=8YFLogxK
U2 - 10.1016/S0167-8760(00)00097-0
DO - 10.1016/S0167-8760(00)00097-0
M3 - Article
C2 - 10828377
AN - SCOPUS:0034237167
SN - 0167-8760
VL - 37
SP - 87
EP - 98
JO - International Journal of Psychophysiology
JF - International Journal of Psychophysiology
IS - 1
ER -